Metoprolol Succinate Teva (Metoprolol Succinate)

Metoprolol succinate is a selective β1‑adrenergic blocker used in several cardiovascular conditions.

• Hypertension: lowers systolic and diastolic blood pressure by reducing cardiac output.
• Chronic stable angina: decreases myocardial oxygen demand, relieving chest pain during exertion.
• Heart failure (reduced ejection fraction): improves survival and reduces hospitalisations by decreasing heart rate and workload.
• Post‑myocardial infarction: lowers the risk of recurrent infarction and sudden cardiac death through rate control and anti‑ischemic effects.

• Metoprolol succinate selectively antagonises β1‑adrenergic receptors in cardiac tissue, inhibiting the effects of endogenous catecholamines. This blockade reduces heart rate, myocardial contractility, and conduction velocity, leading to decreased cardiac output and lower arterial pressure. By diminishing sympathetic stimulation, it also lessens myocardial oxygen consumption and improves ventricular filling in heart failure.

Adverse reactions may vary in frequency and severity.

Common Side Effects

• Fatigue: feeling unusually tired or weak.
• Dizziness: light‑headedness, especially on standing.
• Bradycardia: slower than normal heart rate.
• Cold extremities: reduced blood flow to hands and feet.
• Gastrointestinal upset: nausea or abdominal discomfort.

Serious or Rare Side Effects

• Severe bradycardia: may require medical attention.
• Heart block: impaired electrical conduction.
• Hypotension: markedly low blood pressure.
• Bronchospasm: difficulty breathing, particularly in patients with asthma.
• Depression or mood changes: persistent low mood or anxiety.

Before initiating therapy, consider patient‑specific factors and monitor appropriately.

• Cardiovascular assessment: evaluate heart rate, blood pressure, and cardiac function.
• Respiratory status: avoid in uncontrolled asthma or severe chronic obstructive pulmonary disease.
• Diabetes monitoring: watch for masking of hypoglycaemia symptoms.
• Renal or hepatic impairment: dose may need adjustment based on organ function.
• Concomitant drugs: review for interactions that affect heart rate or blood pressure.
• Store at ambient temperature: keep below 25 °C, retain in original packaging, and protect from moisture.

Metoprolol succinate can alter the effects of several co‑administered medicines.

Major Interactions (Avoid)

• Non‑selective beta‑blockers: additive bradycardia and hypotension.
• Calcium channel blockers (verapamil, diltiazem): profound heart‑rate slowing and AV‑block risk.
• Antidiabetic agents (insulin, sulfonylureas): may mask hypoglycaemia signs.

Moderate Interactions (Monitor Closely)

• Antidepressants (SSRIs, SNRIs): possible increase in plasma metoprolol levels.
• NSAIDs (ibuprofen, naproxen): may reduce antihypertensive effect.
• Thyroid hormones: may diminish metoprolol’s heart‑rate control.